MAPK3 and neoplasm: Among patients with p-MAPK3/1-positive tumour, p-AMPK expression was associated with a significant decrease in colorectal cancer-specific mortality (adjusted HR 0.42; 95% CI: 0.24–0.74), whereas p-AMPK expression was not significantly related with prognosis among patients with p-MAPK3/1-negative tumour (adjusted HR 1.22; 95% CI: 0.85–1.75; p-AMPK-positive vs negative) (Table 3).